Last-resort drug offered to brain cancer patients

NCT ID NCT06404034

First seen Mar 09, 2026 · Last updated Jun 16, 2026 · Updated 14 times

Summary

This program provides gallium maltolate (GaM) to adults aged 18 and older with glioblastoma that has returned or is not responding to standard treatments. The goal is to offer a possible treatment option when no others are available. Patients must be able to swallow capsules and have adequate organ function to participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Partners of Nebraska

    AVAILABLE

    Lincoln, Nebraska, 68516, United States

    Contact

  • Northwell Health

    AVAILABLE

    New York, New York, 10075, United States

    Contact

    Contact Phone: •••-•••-••••

  • University of Miami Sylvester Comprehensive Cancer Center

    AVAILABLE

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.